Document is current

Article History

Received: 3 March 2026

Accepted: 9 July 2026

First Online: 15 July 2026

Declarations

Competing interests: M.A.R.-S., J.G.-M., C.B.-G., C.B.-G., F.M.-B., C.C.-P., A.A., A.A.-V., T.S.-M., R.F.-T., S.K.G., L.G., R.E., F.M.-V., P H.-S., I.L.-L., and E.C.-B. have received support for conference attendance and/or honoraria for advisory or speaking activities from Alnylam Pharmaceuticals and Sobi. M.V.-G., S.G.-G. and D.H-S. declare no conflicts of interest.

Ethical approval: The study adhered to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Approval was obtained from Balearic Islands Research Ethics Committee [CEIm-IB] with the reference code (IB 5669/24 EOm), and all data were anonymized prior to analysis.

AI-assisted technologies: During the preparation and revision of this manuscript, the authors used Julius AI for data analysis assistance, support in the interpretation and presentation of results. The software is identified as Julius AI, web-based platform, accessed between April 2025 and April 2026. All AI-assisted outputs were independently reviewed, verified, and revised by the authors, who made all final decisions regarding the analyses, interpretation, and conclusions reported in the manuscript. The authors assume full responsibility for the accuracy, integrity, and final content of the submitted work.